うつ病と不安を伴うがん患者における反復経頭蓋磁気刺激 (rTMSinCP)
うつ病と不安症のがん患者における反復経頭蓋磁気刺激の安全性と有効性を評価する無作為化非盲検パイロット試験
調査の概要
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- Northwestern University
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
説明
包含基準:
- 女性
- 22~80歳
- 公式の医療記録によって確認された以前のがん(あらゆる種類または段階)の診断を受けていた
- 大うつ病性障害のDSM IV診断を受けています
- HAM-D 24項目のスコアが20以上
- 現在のうつ病エピソードの最小有効用量および期間以上で、1つの以前の抗うつ薬から満足のいく改善を得ることができなかった
- すべての参加者は、研究に登録する前に、署名済みのインフォームド コンセントを提供する必要があります。
除外基準:
- 参加者は脳転移のある乳がんを患っていた
- 試験への参加時に疾患の証拠がある
-他の併発がんの存在または最近の病歴、以下の例外:
- 完全に治療された基底または扁平上皮がんの参加者は、医師が医学的に安定していると判断した場合、研究に含めることができます
- 乳房または子宮頸部の上皮内癌が完全に治療された参加者は、過去1か月以内に化学療法を受けておらず、医師が医学的に安定していると判断した場合、研究に含めることができます
- 結腸に前がん病変のある参加者は、過去1か月以内に化学療法を受けておらず、医師が医学的に安定していると判断した場合、研究に含めることができます
- 参加者は最近手術を受けました(2週間以内)
- 参加者は化学療法を受けています
- 参加者は妊娠中または授乳中です
- 参加者が頭の中または周りに金属製の物体を持っている
- 参加者はペースメーカーを持っています
- -患者の治療精神科医によって決定される不安定な自殺念慮がある
- -過去6か月以内の物質使用障害
- -1時間以上の意識喪失によって定義される頭部外傷/外傷の重大な病歴
- 頭部外傷による発作の繰り返し
- 頭部外傷による明確な認知後遺症と損傷後の認知リハビリテーション
- -参加者を発作の素因とする障害
- 発作のリスクを大幅に高める併用薬の使用。 そのような薬には、神経遮断薬(例: ハロペリドール、ドロペリドール)、クロザピン、三環系抗うつ薬(例. アモキサピン、クロミプラミン)、ブプロピオン (特に即時放出 - IR - 製剤) ドネペジル、精神刺激薬 (ex. メチルフェニデート)、テオフィリンおよび/または発作閾値を下げる他の薬。 これらの薬のいずれかを服用している個人については、研究臨床医が薬と用量を評価して、リスクと利点を判断します。 次に、これらについて個人の主治医と話し合い、その個人を研究から除外すべきかどうかを決定します。
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:右側低周波rTMS
参加者は、右背外側前頭前皮質 (dlPFC) に 1Hz で rTMS を 1 日 1 回 40 分間、週 5 日、合計 6 週間投与されます。
|
他の名前:
|
|
実験的:左側高周波rTMS
参加者は、左背外側前頭前皮質 (dlPFC) に 10Hz で rTMS を 1 日 1 回 40 分間、週 5 日、合計 6 週間投与されます。
|
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Change in Depression Severity (HDRS-17) at Weeks 2, 4, and 6
時間枠:Baseline (Week 0), Week 2, Week 4 and Week 6.
|
This measure reports the overall change in depression severity(HDRS-17) from baseline (Week 0) at each follow-up assessment. Overall Change is defined as the score at each subsequent time point minus the score at Baseline. Scale Information: Name: Hamilton Depression Rating Scale (HDRS-17). Construct: The HDRS-17 is a clinician-administered assessment of depressive symptom severity. Total Score Calculation: The total score is calculated by summing the individual scores of all 17 items. Range: Total scores range from 0 to 52. Directionality: Higher values represent a worse outcome (more severe depression), while lower values represent a better outcome. Calculation Logic: The values reported are the absolute difference of outcomes for each treatment arm. For each participant, the relative change is calculated as: Score at Visit - Baseline Score. Negative numbers indicates a reduction in symptom severity (improvement) and a positive number indicates worsening in symptom severity |
Baseline (Week 0), Week 2, Week 4 and Week 6.
|
|
Relative Change in Depression Severity (HDRS-17) at Weeks 2, 4, and 6
時間枠:Baseline (Week 0), Week 2, Week 4 and Week 6
|
Measure Description: This measure reports the relative (percentage) change in depression severity from baseline (Week 0) at each follow-up assessment. Scale Information: Name: Hamilton Depression Rating Scale (HDRS-17). Construct: The HDRS-17 is a clinician-administered assessment of depressive symptom severity. Total Score Calculation: The total score is calculated by summing the individual scores of all 17 items. Range: Total scores range from 0 to 52. Directionality: Higher values represent a worse outcome (more severe depression), while lower values represent a better outcome. Calculation Logic: The values reported are the mean percentage changes for each treatment arm. For each participant, the relative change is calculated as: ((Score at Visit - Baseline Score) / Baseline Score) * 100. A negative percentage indicates a reduction in symptom severity (improvement). |
Baseline (Week 0), Week 2, Week 4 and Week 6
|
|
Number of Participants With Treatment-Emergent Side Effects (UKU)
時間枠:Baseline (Week 0), Week 2, Week 4, and Week 6
|
Side effects assessed at Weeks 2, 4, 6 via Udvalg for Kliniske Undersøgelser (UKU) scale (48 items, 0=none to 3=severe; higher=worse). 'Treatment-emergent' worsening is a score increase ≥1 from baseline (Tx #1) on any item with possible/probable relation to intervention. Data reported is the count of participants meeting criteria for any of the clusters. Psychic Cluster: concentration, asthenia, sedation, memory, depression, unrest, sleep/dream changes, emotional indifference. Neurological Cluster: dystonia, rigidity, hypokinesia, hyperkinesia, tremor, akathisia, seizures, paresthesia, headache. Autonomic Cluster: accommodation, salivation, nausea/vomiting, diarrhea, constipation, micturition, polyuria, dizziness, tachycardia, sweating. Other Cluster: rash, pruritus, photosensitivity, weight change, menses changes, galactorrhea, gynecomastia, libido changes, erectile dysfunction. |
Baseline (Week 0), Week 2, Week 4, and Week 6
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Change in Anxiety Severity (HAM-A) at Weeks 1, 2, 3, 4, 5, and 6
時間枠:Baseline (Week 0), Week 1- Week 6 (Weekly assessments)
|
Measure Description: The overall change in anxiety severity is assessed using the total score of the Hamilton Anxiety Rating Scale (HAM-A) at each protocol-specified follow-up visit compared to the baseline score at baseline(Week 0) Scale Information: Hamilton Anxiety Rating Scale (HAM-A) Construct: A clinician-rated scale used to measure the severity of a patient's anxiety symptoms, including both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints). Total Score Calculation: The total score is calculated by summing the individual scores of all 14 items. Range: Total scores range from 0 to 56. Directionality: Higher values represent a worse outcome (greater anxiety severity), while lower values represent a better outcome. Calculation Logic: The values reported represent the absolute difference in scores for each treatment arm at every assessment interval minus the score at baseline. |
Baseline (Week 0), Week 1- Week 6 (Weekly assessments)
|
|
Relative Change in Anxiety Severity (HAM-A) at Weeks 1, 2, 3, 4, 5, and 6
時間枠:Baseline(Week 0), Week 1- Week 6 (Weekly assessments)
|
This measure reports the relative (percentage) change in anxiety severity from baseline (Week 0) at each follow-up assessment. Scale name: Hamilton Anxiety Rating Scale (HAM-A). It is a clinician-rated scale used to measure the severity of a patient's anxiety symptoms. The scale consists of 14 items, each defined by a series of symptoms, measuring both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). Each item is scored on a scale of 0 (not present) to 4 (severe). Total score is calculated by summing all 14 items. The total Score ranges from 0 to 56. Higher values represent a worse outcome (greater severity of anxiety), while lower values represent a better outcome. For each protocol-specified time point (Weeks 1-6), the relative change is calculated for as: ((Score at Visit - Baseline Score(Week 0) /Baseline Score)*100. A negative percentage indicates a reduction in symptoms (better outcome). |
Baseline(Week 0), Week 1- Week 6 (Weekly assessments)
|
|
Correlation Between Baseline Anxiety (HAM-A) and Change in Depression Severity (HDRS-17, HAM-D)
時間枠:Baseline (Week 0) and Week 6
|
This measure assesses the relationship between the severity of anxiety symptoms at the start of treatment and the magnitude of depression improvement at Week 6. Scale 1: Hamilton Anxiety Rating Scale (HAM-A). Measures anxiety severity. Total range: 0 to 56. Higher values = worse outcome. Scale 2: Hamilton Depression Rating Scale (HDRS-17, HAM-D). Measures depression severity. Total range: 0 to 50. Higher values = worse outcome. Statistical Analysis & Interpretation: Change Calculation: Depression change is calculated as (Week 6 Score - Baseline Score). A more negative value represents greater improvement. Coefficient: Spearman's rank correlation coefficient (rho) is used. Interpretation: A positive correlation indicates that higher baseline anxiety is associated with higher (less negative) change scores, meaning less improvement. A negative correlation indicates that higher baseline anxiety is associated with lower (more negative) change scores, meaning greater improvement. |
Baseline (Week 0) and Week 6
|
|
Correlation Between Baseline Anxiety (HAM-A) and Harm Avoidance (TCI-R)
時間枠:Baseline
|
This measure assesses the relationship between clinical anxiety symptoms and the personality trait of Harm Avoidance at baseline. Scale Information: Scale 1: Hamilton Anxiety Rating Scale (HAM-A). Measures anxiety severity. Total range: 0 to 56. Higher values = worse outcome. Scale 2: Temperament and Character Inventory-Revised (TCI-R) - Harm Avoidance Subscale. Measures the personality trait of Harm Avoidance. Results are reported as standardized T-scores (mean of 50, standard deviation of 10). The typical range for T-scores is 20 to 80. Outcome Direction: For both scales, higher values represent higher levels of the construct (more anxiety and higher harm avoidance). Statistical Analysis & Interpretation: Coefficient: Spearman's rank correlation coefficient (rho). Interpretation: A positive correlation indicates that individuals with higher clinical anxiety symptoms also tend to score higher on the personality trait of Harm Avoidance. |
Baseline
|
協力者と研究者
スポンサー
協力者
捜査官
- 主任研究者:Mehmet Dokucu, MD, PhD、Northwestern University
出版物と役立つリンク
一般刊行物
- George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, Anderson B, Nahas Z, Bulow P, Zarkowski P, Holtzheimer PE 3rd, Schwartz T, Sackeim HA. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010 May;67(5):507-16. doi: 10.1001/archgenpsychiatry.2010.46.
- Burgess C, Cornelius V, Love S, Graham J, Richards M, Ramirez A. Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ. 2005 Mar 26;330(7493):702. doi: 10.1136/bmj.38343.670868.D3. Epub 2005 Feb 4.
- Janicak PG, O'Reardon JP, Sampson SM, Husain MM, Lisanby SH, Rado JT, Heart KL, Demitrack MA. Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry. 2008 Feb;69(2):222-32. doi: 10.4088/jcp.v69n0208.
- O'Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, McDonald WM, Avery D, Fitzgerald PB, Loo C, Demitrack MA, George MS, Sackeim HA. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007 Dec 1;62(11):1208-16. doi: 10.1016/j.biopsych.2007.01.018. Epub 2007 Jun 14.
- Machado S, Paes F, Velasques B, Teixeira S, Piedade R, Ribeiro P, Nardi AE, Arias-Carrion O. Is rTMS an effective therapeutic strategy that can be used to treat anxiety disorders? Neuropharmacology. 2012 Jan;62(1):125-34. doi: 10.1016/j.neuropharm.2011.07.024. Epub 2011 Jul 27.
- Paes F, Machado S, Arias-Carrion O, Velasques B, Teixeira S, Budde H, Cagy M, Piedade R, Ribeiro P, Huston JP, Sack AT, Nardi AE. The value of repetitive transcranial magnetic stimulation (rTMS) for the treatment of anxiety disorders: an integrative review. CNS Neurol Disord Drug Targets. 2011 Aug;10(5):610-20. doi: 10.2174/187152711796234943.
- Schutter DJ. Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs: a meta-analysis. Psychol Med. 2009 Jan;39(1):65-75. doi: 10.1017/S0033291708003462. Epub 2008 Apr 30.
- Slotema CW, Blom JD, Hoek HW, Sommer IE. Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. J Clin Psychiatry. 2010 Jul;71(7):873-84. doi: 10.4088/JCP.08m04872gre. Epub 2010 Mar 9.
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (推定)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。